End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.2 TWD | -0.44% | +3.17% | -8.80% |
03-13 | Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2021 | 110M 3.37M 269M | Sales 2022 | 188M 5.78M 461M | Capitalization | 4.02B 123M 9.83B |
---|---|---|---|---|---|
Net income 2021 | -47M -1.44M -115M | Net income 2022 | -248M -7.61M -606M | EV / Sales 2021 | 18.4 x |
Net cash position 2021 | 342M 10.48M 835M | Net cash position 2022 | 457M 14.04M 1.12B | EV / Sales 2022 | 18.9 x |
P/E ratio 2021 |
-49.9
x | P/E ratio 2022 |
-15.7
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 31.48% |
1 day | -0.44% | ||
1 week | +3.17% | ||
Current month | +0.74% | ||
1 month | -0.15% | ||
3 months | -10.47% | ||
6 months | -10.59% | ||
Current year | -8.80% |
Managers | Title | Age | Since |
---|---|---|---|
Che Wei Chang
CEO | Chief Executive Officer | - | 07/06/17 |
Chung Cheng Liu
CHM | Chairman | - | 01/01/14 |
Ching Fen Yang
CTO | Chief Tech/Sci/R&D Officer | - | 20/07/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chung Chi Li
BRD | Director/Board Member | - | 16/06/20 |
Che Wei Chang
CEO | Chief Executive Officer | - | 07/06/17 |
Chung Cheng Liu
CHM | Chairman | - | 01/01/14 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 34.2 | -0.44% | 28,603 |
25/04/24 | 34.35 | +0.15% | 29,936 |
24/04/24 | 34.3 | +0.59% | 51,069 |
23/04/24 | 34.1 | -0.44% | 42,956 |
22/04/24 | 34.25 | +3.32% | 70,358 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-8.80% | 68.99M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 6564 Stock